Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Meridian Bioscience, Inc. (VIVO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.55-0.05 (-0.26%)
At close: 04:00PM EST
19.55 0.00 (0.00%)
After hours: 05:29PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close19.60
Open19.61
Bid19.53 x 1200
Ask19.54 x 1300
Day's Range19.28 - 20.13
52 Week Range17.00 - 30.65
Volume288,592
Avg. Volume377,042
Market Cap847.774M
Beta (5Y Monthly)0.42
PE Ratio (TTM)12.07
EPS (TTM)1.62
Earnings DateFeb 03, 2022 - Feb 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateFeb 01, 2019
1y Target Est26.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
33% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VIVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Meridian Bioscience Inc.
    VIVO: What does Argus have to say about VIVO?MERIDIAN BIOSCIENCE INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

    Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December

  • PR Newswire

    Meridian Bioscience Announces Retirement of Chairman David Phillips

    Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight.

  • PR Newswire

    Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing

    Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its Air-Dryable™ LAMP Mix and Air-Dryable™ RT-LAMP 1-Step Mix. These ground-breaking molecular master mixes are specifically designed for fast isothermal amplification of nucleic acid sequences, not only to facilitate the development of point-of-care ambient temperature-stable assays, but also to accelerate diagnosis.

Advertisement
Advertisement